FindTrial
Sign In

Capecitabine, Camrelizumab

DRUG3 trials

Sponsors

Ruijin Hospital

Conditions

Advanced Cervical CancerEsophageal Squamous CancerHead and Neck CancerHepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

Phase 1

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
NCT04508686
Ruijin HospitalAdvanced Cervical Cancer
Start: 2020-08-01End: 2024-08-01Target: 20Updated: 2021-01-29
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
NCT04510818
Ruijin HospitalEsophageal Squamous Cancer, Head and Neck Cancer
Start: 2020-08-01End: 2024-08-01Target: 20Updated: 2020-08-14
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
NCT04932187
Ruijin HospitalHepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
Start: 2021-08-01End: 2025-07-01Target: 20Updated: 2021-09-17

Related Papers

Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.
2025-10-211 citations
Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.
Journal of Clinical Oncology2024-06-01
A phase Ib, open-label, multi-cohort study of metronomic capecitabine plus camrelizumab for treatment of refractory solid tumor: McCrest trial.
Journal of Clinical Oncology2022-06-01